This is a working overview of peptide backbone, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-15 and is reviewed periodically as new material appears.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
=== How they were built and why they were effective === Studies have indicated that when terraces like the ones in the Colca Valley were being constructed, the first step was excavating into the slope, and then a subsequent infilling of the slope. A retaining wall was built to hold the fill material. This wall had many uses, including absorbing heat from the sun during the day and radiating it back out at night, often keeping crops from freezing in the chilling nighttime temperatures, and holding back the different layers of sediment. After the wall is built, the larger rocks would be placed on the bottom, then smaller rocks, then sand, then soil. Since the soil was now level, the water did not rush down the side of the mountain, which is what causes erosion. Previously, this erosion was so powerful that it had potential to wipe out major areas of the Inca road, as well as wash away all of the nutrients and fertile soil. Not only was it serving a purpose in crops it also was able to support canals due to the high altitude which would accumulate water and further transport it to other sections. Since the soil never washed away, nutrients would always be added from previously grown crops year after year. The Inca even grew specific crops together, to balance out the optimal amount of nutrients for all plants. For example, a planting method is known as "three sisters" incorporated the growth of corn, beans, and squash in the same terrace.
=== Gelling agents === Agar, a gelatinous substance derived from red algae, has a number of commercial uses. It is a good medium on which to grow bacteria and fungi, as most microorganisms cannot digest agar. Alginic acid, or alginate, is extracted from brown algae. Its uses range from gelling agents in food, to medical dressings. Alginic acid also has been used in the field of biotechnology as a biocompatible medium for cell encapsulation and cell immobilization. Molecular cuisine is also a user of the substance for its gelling properties, by which it becomes a delivery vehicle for flavours.
These weight reduction treatments include the injection of HCG, a drug which has not been approved by the Food and Drug Administration as safe and effective in the treatment of obesity or weight control. There is no substantial evidence that HCG increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or "normal" distribution of fat, or that it decreases the hunger and discomfort associated with calorie-restrictive diets. There was a resurgence of interest in the "HCG diet" following promotion by Kevin Trudeau, who was banned from making HCG diet weight-loss claims by the U.S. Federal Trade Commission in 2008, and eventually jailed over such claims. A 1976 study in the American Journal of Clinical Nutrition concluded that HCG is not more effective as a weight-loss aid than dietary restriction alone. A 1995 meta analysis found that studies supporting HCG for weight loss were of poor methodological quality and concluded that "there is no scientific evidence that HCG is effective in the treatment of obesity; it does not bring about weight-loss or fat-redistribution, nor does it reduce hunger or induce a feeling of well-being". On November 15, 2016, the American Medical Association (AMA) passed policy that "The use of human chorionic gonadotropin (HCG) for weight loss is inappropriate."
The overwhelming majority of MRONJ diagnoses, however, were associated with intravenous administration of bisphosphonates (94%). Only the remaining 6% of cases arose in patients taking bisphosphonates orally. Although the total United States prescriptions for oral bisphosphonates exceeded 30 million in 2006, less than 10% of MRONJ cases were associated with patients taking oral bisphosphonate drugs. Studies have estimated that BRONJ occurs in roughly 20% of patients taking intravenous zoledronic acid for cancer therapy and in between 0–0.04% of patients taking orally administered bisphosphonates. Owing to prolonged embedding of bisphosphonate drugs in the bone tissues, the risk for MRONJ is elevated even after stopping the administration of the medication for several years. Patients who stopped taking anti-angiogenic drugs are exposed to the same risk as patients who have never taken the drugs because anti-angiogenic drugs do not normally reside in the body for a long period of time. Risk factors include:
Information about blood components and products Consent Patient identification Sample labelling Storage, transport, and cold chain concepts Infusion rates/times and fluid compatibility Patient monitoring Transfusion reactions: how to recognise, manage and report TPs collaborate with department heads and senior management to facilitate mandatory and non-mandatory staff education/training consistent with regulatory requirements/recommendations.
Sources: en.wikipedia.org
=== Salt of hartshorn === Compositions containing ammonium carbonate have long been known. They were once produced commercially, formerly known as sal volatile or salt of hartshorn. It was obtained by the dry distillation of nitrogenous organic matter such as hair, horn, leather. In addition to ammonium bicarbonate, this material contains ammonium carbamate (NH4CO2NH2), and ammonium carbonate ((NH4)2CO3). It is sometimes called ammonium sesquicarbonate. It possesses a strong ammoniacal smell, and on digestion with alcohol, the carbamate is dissolved leaving a residue of ammonium bicarbonate. A similar decomposition takes place when the sesquicarbonate is exposed to air.
=== Alzheimer's disease === Oxidative stress has been linked to onset of Alzheimer's disease (AD) Since the NQO1*2 polymorphism affects the NQO1 activity and hence increase in oxidative stress, it has been postulated that this might increase the susceptibility of affected subjects for developing AD. A study conducted with a Chinese population consisting of 104 LOAD patients and 128 control patients disproved this hypothesis.
By the mid-2000s, Liebling had nearly disappeared from public life. He spent his days isolated in his parents' basement, trapped in a relentless cycle of addiction and self-destructive behavior. The toll of decades of substance abuse was evident in his skeletal frame, which was covered in sores and barely functioning, leading many to believe he was beyond redemption. This chapter of his life, which took an unexpected turn, became the subject of the documentary Last Days Here (2011), directed by Don Argott and Demian Fenton. Filmed over four years, the documentary follows Liebling, who is in his 50s and living in the basement of his parents' house in Alexandria, Virginia, as he battles severe drug addiction. His friend, manager, and longtime Pentagram fan Sean "Pellet" Pelletier took it upon himself to pull Liebling out of the abyss and get him back to music and a healthier life. Alongside Pelletier, the film features interviews with former Pentagram members, friends, Liebling's parents, and his then-girlfriend, Hallie. The documentary ends on a hopeful note; by 2010, Pentagram had returned to the stage, and Liebling was sober, married to Hallie, and expecting their first child. When Argott and Fenton first met Liebling, they had little hope that his story would lead anywhere. "Bobby was in such bad shape when Pellet introduced us to him that we didn't think his story would go anywhere. It really seemed like he was going to smoke himself to death in his parents' basement, something we weren't interested in documenting," Fenton recalled.
=== Antimicrobial peptides === As an arthropod, S. mutilans has no acquired immune system, which leads to the development of numerous antimicrobial peptides in its innate immune system. An antimicrobial peptide named scolopendrasin VII was discovered in S. mutilans . The peptide stimulates actin polymerization; the subsequent chemotactic migration of macrophages was also stimulated by this peptide through activating ERK (extracellular signal-regulated kinases) and protein kinase B (Akt) activity. Scolopendrasin VII was also found to stimulate chemotactic migration of FPR1-transfected RBL-2H3 cells (mast cells), and directly binds to FPR1. Scolopin 1 and 2 are antimicrobial peptides identified from the venom of S. mutilans. These peptides were identified by Sephadex gel filtration and RP-high-performance liquid chromatography. Both scolopin 1 and 2 were reported to show intense antimicrobial activities, which includes both Gram-positive and Gram-negative bacteria and fungi. It was also reported to have moderate haemolytic effects on human and rabbit red blood cells. Scolopin 1 holds the potential as an antimicrobial agent. Scolopin 2 was found able to inhibit HeLa cell proliferation in cancer research; it was also found to combine with mitochondria, which allows it to regulate apoptosis in pathways in HeLa cells. Scolopin 2 is able to significantly suppress tumour growth in mice trials without causing any side effects. It was hence considered a strong candidate for HeLa cervical cancer treatment.
== Health concerns == Health experts are concerned about the increased consumption and popularity of functional beverages. Most functional beverages are sweetened, and consumption of sweetened beverages is associated with higher levels of obesity and heart disease. Most of these drinks contain significant amounts of sugars and hence calories, which would add to discretionary and total caloric intake. As such, these ingredients pose health risks because of what they contain (sugar and caffeine) or what they replace in the diet (vitamin and mineral-rich foods).
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.